ALERT B&C Corporation announces results for its first quarter ended December 31, 2007 and corporate update



    LAVAL, QC, March 3 /CNW Telbec/ - ALERT B&C Corporation (the
"Corporation") (TSX Venture Exchange: ACB) today issued its consolidated
financial results for the three month period ended December 31, 2007. It is
also providing an update on its operations, including some modifications to
management team and Board of directors, the assembly and sales & marketing of
its proprietary Mass Spectrometer TRAKER(TM) equipment.
    The Corporation is a BioDefence company dedicated to providing superior
quality technologies, products and solutions to the BioDefence Market, in
order to improve and maintain the safety and the security of individuals
worldwide. The products offered by the Corporation are Biological and Chemical
detection and identification equipment, the TRAKER(TM), designed for the
identification of dangerous and toxic agents.

    
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------
                                        Three-month period ended December 31
                                                      2007              2006
    -------------------------------------------------------     -------------
    -------------------------------------------------------     -------------
    Sales                                      $         -       $         -
    Cost of sales                                        -                 -
    -------------------------------------------------------     -------------
    Gross profit                                         -                 -
    -------------------------------------------------------     -------------

    Expenses
      General and administrative                   364,408           138,444
      Production cost                              104,748                 -
      Commercialization and market development      50,975             3,577
      Research and development                      37,475                 -
      Stock-based compensation                      10,801                 -
      Amortization of patents                        5,575             7,007
      Amortization of property and equipment        12,724                 -
      Interest income                              (16,296)                -
    -------------------------------------------------------     -------------
                                                   570,410           149,028
    -------------------------------------------------------     -------------

    Net loss and comprehensive income          $  (570,410)      $  (149,028)
    -------------------------------------------------------     -------------
    -------------------------------------------------------     -------------

    Basic and diluted loss per common share    $     (0.01)      $     (0.01)
    -------------------------------------------------------     -------------
    -------------------------------------------------------     -------------

    Weighted average common shares outstanding
    - basic and diluted                         49,603,860        19,331,233
    -------------------------------------------------------     -------------
    -------------------------------------------------------     -------------
    

    There were no revenues during the first quarter of fiscal 2008. General
and administrative expenses, production and commercialization and market
development costs amounted to $364,408, $104,748 and $50,975 respectively in
the first quarter of fiscal 2008 as compared to $138,444, nil and $3,577 in
the same quarter of 2007. The major part of this increase was due to the
resumption of corporate activities following the March 2007 financing. These
activities include the hiring of additional employees and consultants for
ramping up the production of instruments and to support the market development
of the Corporation's TRAKER(TM) equipment.
    During the first quarter of fiscal 2008, the Corporation spent $37,475 in
research and development expenses (R&D) in refining development and
prototyping of the TRAKER(TM) equipment. During the same quarter of 2007, no
R&D expenses were incurred.
    In fiscal year 2007, the Corporation received two purchase orders for its
TRAKER(TM) equipment. The Corporation received the second order for its
proprietary Mass Spectrometer TRAKER(TM) from the "Services d'Incendie et de
Secours (S.D.I.S.) from Bouches-du-Rhône" in France in the second quarter of
2007, (March 22nd, 2007). The first order had been placed by the
"Marins-Pompiers" of Marseille, see prior press release dated December 18th,
2006. The Corporation encountered operational difficulties which have
prevented it to fulfill these orders to date, which resulted in the
Corporation modifying its original assembly planning and repatriating all its
production capacity to Montreal. Therefore the Corporation is now assembling
the equipment and expects to deliver them in the third quarter of fiscal 2008.
The Corporation is diligently working on developing the North American market
in order to sell additional TRAKER(TM) equipment in fiscal 2008. The
Corporation is of the opinion that it is now better positioned to answer the
demand for similar systems. Furthermore, following the production of MAB
("Metastable Atom Bombardment") Sources, the Corporation will also be ready to
fulfill potential orders of MAB Sources for the North American market in
fiscal 2008.
    At the end of fiscal 2007 and subsequent to a thorough scientific review
and analysis of the two patent applications acquired in the assets purchased
from ABIONIX Sarl, the Corporation has recognized a write-down of $193,344 for
the two patent applications previously acquired for an amount of $195,083. The
Corporation did not foresee that these patent applications could ever be
useful and be issued because of an intrinsic flaw in the design proposed in
the two patent applications concerning a MAB-EI source. Furthermore, the
Corporation was of the opinion that these patent applications could not have
been issued on their own because of existing prior art based on the
combination of public domain EI (Electronic Impact) technology and on our
patented MAB (Metastable Atom Bombardment) technology. Under the terms of the
purchase agreement with ABIONIX Sarl another 250,000 shares were to be
released following the receipt of a second order and 500,000 shares were to be
released, at the time that the two patent applications would have been issued.
Since the Corporation recognized a write-down on the two patent applications,
the 500,000 shares will not be released and will be returned to treasury.
250,000 shares should be released during fiscal 2008. Out of the total
outstanding number of shares of the Corporation (49,603,860) this transaction
represented in whole 2.25 million shares.
    Net loss for the first quarter of fiscal 2008 was $570,410 ($0.01 per
share) compared to $149,028 ($0.01 per share) for the same period last year.
On December 31, 2007, the Corporation had cash and cash equivalents of
$867,821 compared to $(92,650) at the end of the last fiscal year ended
September 30, 2007.
    As at December 31, 2007 there were 49,603,860 common shares outstanding,
1,602,970 options outstanding at an average exercise price of $0.42,
14,312,944 warrants at an exercise price of $0.25 and 2,862,589 broker
warrants at an exercise price of $0.15.

    Update on Management and Board

    The Corporation had appointed as its CFO and COO, Mr. Brian Lukian, in
late February 2007, however, he resigned in March 2007. Following Mr. Lukian's
departure, the Corporation gave the interim CFO position to Mr. Costa
Papadopoulos under a probation period. Mr. Papadopoulos left in December 2007
to pursue his career elsewhere. In May 2007, Mr. Romano Robusto was appointed
COO and Vice-President Business development of the Corporation. The Board is
now comprised of Dr. Suzanne L. Lebel (Chairman of the Board), Mr. Frédéric
Esplat, Mr. Paul Morgante, Pete Phelan, Marc Vermette and Dr. Zofia Zukowska
and management of Dr. Suzanne L. Lebel (President & CEO), Mr. Romano Robusto
(COO and VP Business Development), Mrs. Myriam Theberge (Secretary-Treasurer).
The Corporation is currently seeking to fill the position of CFO.

    About the Corporation

    Founded in 1995, the Corporation is a BioDefence company dedicated to
supplying the BioDefence market with high quality technologies, products and
solutions, in order to improve and maintain the safety and the security of
individuals worldwide. For more information about the Corporation visit our
new website at www.alertbc.com.

    This press release contains forward-looking statements, which reflect the
Corporation's current expectations regarding future events. The
forward-looking statements involve risks and uncertainties. Actual events
could differ materially from those projected herein. Investors should consult
the Corporation's quarterly filings and annual reports for additional
information on risks and uncertainties relating to these forward-looking
statements. The reader is cautioned not to rely on these forward-looking
statements. The Corporation disclaims any obligation to update these
forward-looking statements

    The TSX Venture Exchange does not accept responsibility for the adequacy
    or accuracy of this press release.
    %SEDAR: 00012523E




For further information:

For further information: Investor relations: Dr. Suzanne L. Lebel,
Chairman, President & CEO, ALERT B&C Corporation, (450) 688-4499, Fax: (450)
688-9100, info@alertbc.com; Media relations: Jean-Pierre Trudel, President,
Jean-Pierre Trudel & Associates Inc., (514) 347-6111, Fax: (514) 693-1253,
jp.trudel@videotron.ca

Organization Profile

ALERT B&C CORPORATION

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890